Efficacy and safety of Ivabradine (Coralan) in the treatment of stable angina pectoris

Serdia Pharmaceuticals India Pvt Ltd Mumbai0 个研究点目标入组 300 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1) Male and female patients between 18 years to 75 years of age
•2) Confirmed case of Coronary Artery Disease (CAD) documented by either of the following:
•a.History of stable angina (on treatment with anti-anginal drug for at least last 3 months prior to inclusion)
•b.Previous myocardial infarction of > 6 months duration prior to inclusion
•c.Positive exercise tolerance test (ETT, based on available report)
•d.Previous revascularization of > 6 months prior to inclusion (percutaneous or surgical)
•e.Angiographic evidence that one or more major coronary arteries had narrowed by 50% or more (ETT, based on available report)
•3) Given written informed consent to participate in the study and agree for regular follow-up

•1) Resting heart rate below 60 beats per minute
•2) Heart failure
•3) History of myocardial infarction/ stroke of < 6 months prior to inclusion
•4) AV block, SA block and/or sick-sinus syndrome
•5) Symptomatic hypotension
•6) Unstable/ Prinzmetal angina
•7) Atrial fibrillation/ flutter, arrhythmias
•8) Severe hepatic abnormalities
•9) Intolerance and any other clinical condition likely to interfere in the study conduct
•10) History of drug abuse/ alcohol abuse
•11) Pregnancy/ Lactation

发起方

Serdia Pharmaceuticals India Pvt Ltd Mumbai